The American Journal of Medicine
Volume 122, Issue 4 , Pages 356-365 , April 2009

Long-Acting Calcium Antagonists in Patients with Coronary Artery Disease: A Meta-Analysis

This work was presented in part at the Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, 2007.

  • Sripal Bangalore, MD, MHA
    • ,
  • Sanobar Parkar, MD, MPH
    • ,
  • Franz H. Messerli, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Franz H. Messerli, MD, Director, Hypertension Program, Division of Cardiology, St. Luke's-Roosevelt Hospital, 1000 10th Avenue, Suite 3B-30, New York, NY 10019

References 

  1. Berenson A. Big drug makers see sales decline with their image. New York Times; 2005;November 14
  2. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?. JAMA. 1996;276(16):1328–1331
  3. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17(1):1–12
  4. Bradburn MJ, Deeks J, Altman DG. Sbe24: metan – an alternative meta-analysis command. Stata Technical Bull Reprints. 1998;8:86–100
  5. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7(8):889–894
  6. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188
  7. Steichen T. Update of tests for publication bias in meta-analysis. Stata Technical Bull Reprints. 2000;10:70
  8. Lubsen J, Wagener G, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens. 2005;23(3):641–648
  9. Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48(3):374–384
  10. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–2225
  11. Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol. 2004;93(8):969–973
  12. Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res. 2004;27(3):181–191
  13. Dens JA, Desmet WJ, Coussement P, et al. Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. Heart. 2003;89(8):887–892
  14. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure (Prospective Randomized Amlodipine Survival Evaluation Study Group). N Engl J Med. 1996;335(15):1107–1114
  15. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events (PREVENT Investigators). Circulation. 2000;102(13):1503–1510
  16. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET) (Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group). Eur Heart J. 1996;17(1):104–112
  17. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III (Vasodilator-Heart Failure Trial (V-HeFT) Study Group). Circulation. 1997;96(3):856–863
  18. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris (The Angina Prognosis Study in Stockholm (APSIS)). Eur Heart J. 1996;17(1):76–81
  19. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS). Am J Cardiol. 1996;77(5):365–369
  20. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. JAMA. 2003;290(21):2805–2816
  21. Levine TB, Bernink PJ, Caspi A, et al. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study (Mortality Assessment in Congestive Heart Failure Trial). Circulation. 2000;101(7):758–764
  22. Bestehorn HP, Neumann FJ, Buttner HJ, et al. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial. J Am Coll Cardiol. 2004;43(12):2160–2165
  23. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364(9437):849–857
  24. Furberg CD, Psaty BM, Meyer JV. Nifedipine (Dose-related increase in mortality in patients with coronary heart disease). Circulation. 1995;92(5):1326–1331
  25. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991;67(15):1295–1297
  26. Messerli FH, Staessen JA. Safety of calcium antagonists: more ACTION. Am J Med. 2005;118(12):1418–1420
  27. The effect of diltiazem on mortality and reinfarction after myocardial infarction (The Multicenter Diltiazem Postinfarction Trial Research Group). N Engl J Med. 1988;319(7):385–392
  28. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction (The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group). Circulation. 1991;83(1):52–60
  29. Kostis JB, Lacy CR, Cosgrove NM, Wilson AC. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. Am Heart J. 1997;133(5):550–557
  30. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000;356(9246):1949–1954
  31. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension. 2007;50(1):181–188

 Funding: None.

 Conflicts of Interest: Sripal Bangalore: no disclosures; Sanobar Parkar: no disclosures; Franz H Messerli: Speakers' Bureau—Abbott, GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Forest, Sankyo, Sanofi. Research/Grants—GlaxoSmithKline, Pfizer, Novartis, CardioVascular Therapeutics.

 Authorship: All authors had access to the data and had a role in writing the manuscript.

PII: S0002-9343(08)01104-2

doi: 10.1016/j.amjmed.2008.09.043

The American Journal of Medicine
Volume 122, Issue 4 , Pages 356-365 , April 2009

Article Tools

* Image Usage & Resolution